Mirati announces updated data from ongoing trial of single agent sitravatinib
Mirati Therapeutics announced the completed stage 1 safety and efficacy data from the ongoing Phase 1b clinical trial of single agent sitravatinib in patients with certain classes of oncogenic mutations. The data for a cohort of patients harboring CBL mutations were presented in a proffered poster session at the European Society for Medical Oncology 2018 Congress in Munich, Germany. The presentation provided an update from the pre-planned expansion cohort of the Phase 1b clinical trial of single agent sitravatinib in patients with CBL inactivating mutations. Eight patients were evaluable as of the data cut-off on August 27, 2018. In the subset of evaluable NSCLC patients, 1/2 confirmed partial responses were observed with 2/2 patients experiencing tumor regression. In the subset of evaluable melanoma patients, 1/2 confirmed partial responses in evaluable patients were observed with 1/2 patients experiencing tumor regression. In the subset of evaluable patients with other solid tumors, 2/4 had stable disease with 2/4 experiencing tumor regression. CBL mutations are present in 1.5% of NSCLC, 3.5% of melanoma, and 2% of cancers of unknown origin.